Company Filing History:
Years Active: 2024-2025
Title: Tyler Albin: Innovator in Dystrophin Therapeutics
Introduction
Tyler Albin is a notable inventor based in San Diego, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of therapies for muscle dystrophies. With a total of 2 patents, Albin's work focuses on innovative solutions for treating conditions such as Duchenne muscular dystrophy.
Latest Patents
Albin's latest patents include the development of anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping. These patents disclose antibody oligonucleotide conjugates and pharmaceutical compositions that induce an alteration in an incorrectly spliced dystrophin mRNA transcript to promote exon 44 skipping. The methods described in these patents aim to treat muscle dystrophy, including Duchenne muscular dystrophy, by administering these conjugates or pharmaceutical compositions.
Career Highlights
Tyler Albin is currently employed at Avidity Biosciences, Inc., where he continues to advance his research in the field of muscle dystrophies. His work is characterized by a commitment to developing effective treatments that can significantly improve the quality of life for patients suffering from these conditions.
Collaborations
Albin collaborates with talented professionals in his field, including Beatrice Diana Darimont and Usue Etxaniz Irigoien. These collaborations enhance the innovative potential of his research and contribute to the advancement of therapeutic solutions.
Conclusion
Tyler Albin's contributions to the field of biotechnology, particularly in the treatment of muscle dystrophies, highlight his role as an influential inventor. His patents and ongoing work at Avidity Biosciences, Inc. reflect a dedication to improving patient outcomes through innovative therapies.